MedCity News

Why Specialized UM Delivers on Every NICU Outcome

Spotting Alzheimer’s Years Earlier Through AI and Clinically Meaningful Insights

A few minutes of interaction with a digital tablet and speaking can reveal patterns that once required advanced imaging, years of observation, or were just completely undetectable.

By David Bates

Hospitals, Providers

Closeup shot of a group of medical practitioners joining their hands together in a huddle

Why Endeavor Health Refuses to Silo Its Value-Based Care Strategy

Lakshmi Halasyamani, chief clinical officer at Endeavor Health, thinks value-based care isn't really about payment models. To her, this work centers on understanding patients' clinical, social and financial circumstances well enough to make care plans that actually work for their lives.

By Katie Adams

BioPharma, Pharma

Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders

Argenx’s first acquisition is the buyout of Forte Biosciences, a company with a lead drug that has early clinical validation in celiac disease and vitiligo. Argenx executives say this antibody complements its blockbuster product Vyvgart, offering a different mechanism of action but similar pipeline-in-a-product potential.

By Frank Vinluan

Latest Video

Latest News

MedCity Influencers

Prior Authorization Is Draining Revenue: Why Automation Has Become a Strategic Imperative

When staff are overextended and patients face delays or abandon care, the issue is no longer a narrow administrative burden. It becomes a business, financial, and access challenge that demands a different operating model.

By Terry Russell

MedCity Influencers

Doctor at work. Medical professional using tablet in clinic office. Medicine and health care concept.

How AI Inside Clinical Workflows Is Unlocking Patient Throughput

The question is not whether the technology is impressive. The question is whether it shows up at the right time, with the right information, inside the workflow where the decision is being made. Anything else is just another report.

By Jonathan Shoemaker

Artificial Intelligence, Health Tech, Legal

Ai chatbot interface on a screen with glowing pink speech bubbles representing conversation and coding language for artificial intelligence development

What Happens When Patients Trust AI Over Their Doctor?

As patients increasingly bring AI chatbot advice into exam rooms, where does liability land when that advice goes wrong? Health law attorney Meghan O'Connor said the answer still isn’t clear, but silence is the riskiest response for providers.

By Katie Adams

BioPharma, Startups

Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug

Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition.

By Frank Vinluan

Health Tech

Digital generated image of multi layered dollar sign making swirl pattern.

Candid Health Snags $120M for AI RCM Platform

Candid's Series D round was led by Sixth Street Growth, with participation from Oak HC/FT, 8VC and Y Combinator.

By Marissa Plescia

MedCity Influencers

Why Value-Based Care Only Works If You’ve Tamed Costs

VBC aligns reimbursements to outcomes, emphasizing the quality and effectiveness, not quantity, of healthcare activities. But the same cost constraints driving interest in VBC can also turn it into a liability.

By Sajeed Chowdhury

MedCity Influencers

Medicine Understands Trauma’s Impact, But Rarely Asks About It

A core principle of trauma-informed care is understanding that past and ongoing exposure to stress and trauma can directly shape health outcomes. But by remaining blind to these histories, the medical community severely limits its ability to address the very drivers of the diseases it is trying to cure.

By Dr. Roy Wade and Dr. Roy Ziegelstein

BioPharma, Payers

A Prescription for Drug Costs: Inject Transparency and Improve Accessibility

Drug spending continues to grow, but that doesn’t mean that everyone is getting the medicines that they need. A panel at MedCity News’ Bullseye event discussed the evolution of the prescription drug marketplace.

By Frank Vinluan

Health Tech, Startups

What Health Tech Investors Love in Founders — and What They Can’t Stand

Health tech investors say the founders who win them over aren't the ones with all the answers, but the ones who know exactly what they don't know — and build a team to cover the gap.

By Katie Adams

Health Tech, Payers

Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail

Priority Health partnered with Color Health and Grail to offer self-funded employers virtual cancer navigation, support and multi-cancer early detection beginning in 2027.

By Marissa Plescia

MedCity Influencers

AI Will Reshape the Patient Experience

We’re about to enter a world beyond just talking to a chat tool about your health. AI tools are on the precipice of being able to take action on their advice.

By Peter Horadan

MedCity Influencers

Jet trail creating dollar sign in blue sky with clouds startup capital

Healthcare’s Next Source of Alpha Is Moving Upstream

The question is no longer whether healthcare innovation is accelerating. The question is where investors gain access to generate the strongest returns.

By Derek Minno

BioPharma, Pharma

DNA molecular structure with sequencing data of human genome analysis.

CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO

Scribe Therapeutics’ IPO will support a pipeline led by a genetic medicine that represses expression of its target gene without making permanent changes. Common chronic cardiometabolic conditions are Scribe’s initial focus as the biotech works to bring genetic medicines beyond rare diseases.

By Frank Vinluan

Artificial Intelligence, Health Tech

Healthcare Investors Are Rewriting the ROI Playbook from Cost-Cutting to Cash Flow

Unlike past healthcare tech waves sold on cost savings, AI is proving it can generate new revenue — with returns as high as 100x, according to a panel of investors at MedCity News' Bullseye event.

By Katie Adams